Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma
The advent of immune-checkpoint inhibitors (ICIs) led to significant improvements in the treatment of patients with advanced melanoma and resulted in durable tumor responses in a considerable number of advanced melanoma patients. Next to the immune-mediated anti-neoplastic effects, ICIs may cause va...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Immuno |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-5601/2/2/20 |
| _version_ | 1797486224850550784 |
|---|---|
| author | Maximilian Haist Henner Stege Verena Maikranz Maria Halley Blanco Stephan Grabbe Carmen Loquai |
| author_facet | Maximilian Haist Henner Stege Verena Maikranz Maria Halley Blanco Stephan Grabbe Carmen Loquai |
| author_sort | Maximilian Haist |
| collection | DOAJ |
| description | The advent of immune-checkpoint inhibitors (ICIs) led to significant improvements in the treatment of patients with advanced melanoma and resulted in durable tumor responses in a considerable number of advanced melanoma patients. Next to the immune-mediated anti-neoplastic effects, ICIs may cause various immune-related adverse events (irAEs), often requiring early discontinuation of therapy. By contrast, cutaneous irAE rarely enforce treatment discontinuation but may represent simple and robust predictive markers for treatment response. The relevance of irAEs as clinical markers for an improved response to immunotherapy is still debated. We report here on two patients with multifocal metastatic melanoma who developed the rare event of generalized poliosis during combined immunotherapy with ipilimumab plus nivolumab, followed by a near-complete and durable response. Our observations suggest that poliosis may be a useful and simple clinical indicator of anti-tumor immunity, clinical response and favorable survival outcome in advanced melanoma patients treated with ICI. |
| first_indexed | 2024-03-09T23:31:11Z |
| format | Article |
| id | doaj.art-65f6587fb6014ccbbe11620d9a269c93 |
| institution | Directory Open Access Journal |
| issn | 2673-5601 |
| language | English |
| last_indexed | 2024-03-09T23:31:11Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Immuno |
| spelling | doaj.art-65f6587fb6014ccbbe11620d9a269c932023-11-23T17:09:03ZengMDPI AGImmuno2673-56012022-03-012230731610.3390/immuno2020020Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic MelanomaMaximilian Haist0Henner Stege1Verena Maikranz2Maria Halley Blanco3Stephan Grabbe4Carmen Loquai5Department of Dermatology, University Medical Center of the Johannes-Gutenberg University Mainz, 55131 Mainz, GermanyDepartment of Dermatology, University Medical Center of the Johannes-Gutenberg University Mainz, 55131 Mainz, GermanyDepartment of Dermatology, University Medical Center of the Johannes-Gutenberg University Mainz, 55131 Mainz, GermanyDepartment of Dermatology, University Medical Center of the Johannes-Gutenberg University Mainz, 55131 Mainz, GermanyDepartment of Dermatology, University Medical Center of the Johannes-Gutenberg University Mainz, 55131 Mainz, GermanyDepartment of Dermatology, University Medical Center of the Johannes-Gutenberg University Mainz, 55131 Mainz, GermanyThe advent of immune-checkpoint inhibitors (ICIs) led to significant improvements in the treatment of patients with advanced melanoma and resulted in durable tumor responses in a considerable number of advanced melanoma patients. Next to the immune-mediated anti-neoplastic effects, ICIs may cause various immune-related adverse events (irAEs), often requiring early discontinuation of therapy. By contrast, cutaneous irAE rarely enforce treatment discontinuation but may represent simple and robust predictive markers for treatment response. The relevance of irAEs as clinical markers for an improved response to immunotherapy is still debated. We report here on two patients with multifocal metastatic melanoma who developed the rare event of generalized poliosis during combined immunotherapy with ipilimumab plus nivolumab, followed by a near-complete and durable response. Our observations suggest that poliosis may be a useful and simple clinical indicator of anti-tumor immunity, clinical response and favorable survival outcome in advanced melanoma patients treated with ICI.https://www.mdpi.com/2673-5601/2/2/20immune-checkpoint inhibitorsimmune-related adverse eventsPoliosisadvanced melanomapredictive biomarkerscase report |
| spellingShingle | Maximilian Haist Henner Stege Verena Maikranz Maria Halley Blanco Stephan Grabbe Carmen Loquai Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma Immuno immune-checkpoint inhibitors immune-related adverse events Poliosis advanced melanoma predictive biomarkers case report |
| title | Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma |
| title_full | Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma |
| title_fullStr | Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma |
| title_full_unstemmed | Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma |
| title_short | Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma |
| title_sort | poliosis is associated with response to checkpoint inhibitor therapy a case report of two patients with multifocal metastatic melanoma |
| topic | immune-checkpoint inhibitors immune-related adverse events Poliosis advanced melanoma predictive biomarkers case report |
| url | https://www.mdpi.com/2673-5601/2/2/20 |
| work_keys_str_mv | AT maximilianhaist poliosisisassociatedwithresponsetocheckpointinhibitortherapyacasereportoftwopatientswithmultifocalmetastaticmelanoma AT hennerstege poliosisisassociatedwithresponsetocheckpointinhibitortherapyacasereportoftwopatientswithmultifocalmetastaticmelanoma AT verenamaikranz poliosisisassociatedwithresponsetocheckpointinhibitortherapyacasereportoftwopatientswithmultifocalmetastaticmelanoma AT mariahalleyblanco poliosisisassociatedwithresponsetocheckpointinhibitortherapyacasereportoftwopatientswithmultifocalmetastaticmelanoma AT stephangrabbe poliosisisassociatedwithresponsetocheckpointinhibitortherapyacasereportoftwopatientswithmultifocalmetastaticmelanoma AT carmenloquai poliosisisassociatedwithresponsetocheckpointinhibitortherapyacasereportoftwopatientswithmultifocalmetastaticmelanoma |